Lymphocyte immune globulin
Products billed under this code include Atgam.
Payment limit per 250 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Atgam.
Payment limit per 250 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Atgam | Pfizer Inc | 00009-7224-02 | 5 | $27,545.36 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5,509.072 | −$39.89 | 250 MG | Lymphocyte immune globulin | v1, posted September 17, 2026 |
| 3Q26 | $5,548.962 | +$256.53 | 250 MG | Lymphocyte immune globulin | v1, posted September 15, 2026 |
| 2Q26 | $5,292.432 | −$15.498 | 250 MG | Lymphocyte immune globulin | v1, posted September 15, 2026 |
| 1Q26 | $5,307.93 | +$172.84 | 250 MG | Lymphocyte immune globulin | v1, posted September 15, 2026 |
| 4Q25 | $5,135.09 | +$121.98 | 250 MG | Lymphocyte immune globulin | v1, posted September 8, 2026 |
| 3Q25 | $5,013.11 | +$636.82 | 250 MG | Lymphocyte immune globulin | v1, posted March 10, 2026 |
| 2Q25 | $4,376.29 | +$20.557 | 250 MG | Lymphocyte immune globulin | v1, posted March 10, 2026 |
| 1Q25 | $4,355.733 | +$387.287 | 250 MG | Lymphocyte immune globulin | v1, posted December 19, 2025 |
| 4Q24 | $3,968.446 | −$14.148 | 250 MG | Lymphocyte immune globulin | v1, posted June 11, 2025 |
| 3Q24 | $3,982.594 | +$367.79 | 250 MG | Lymphocyte immune globulin | v1, posted June 11, 2025 |
| 2Q24 | $3,614.804 | +$23.346 | 250 MG | Lymphocyte immune globulin | v1, posted March 11, 2025 |
| 1Q24 | $3,591.458 | +$336.585 | 250 MG | Lymphocyte immune globulin | v1, posted December 19, 2024 |
| 4Q23 | $3,254.873 | +$265.436 | 250 MG | Lymphocyte immune globulin | v1, posted October 10, 2024 |
| 3Q23 | $2,989.437 | −$11.853 | 250 MG | Lymphocyte immune globulin | v1, posted June 5, 2024 |
| 2Q23 | $3,001.29 | −$1.538 | 250 MG | Lymphocyte immune globulin | v1, posted February 23, 2024 |
| 1Q23 | $3,002.828 | +$220.657 | 250 MG | Lymphocyte immune globulin | v1, posted December 6, 2023 |
| 4Q22 | $2,782.171 | −$116.126 | 250 MG | Lymphocyte immune globulin | v1, posted June 22, 2023 |
| 3Q22 | $2,898.297 | +$542.351 | 250 MG | Lymphocyte immune globulin | v1, posted June 9, 2023 |
| 2Q22 | $2,355.946 | +$0.583 | 250 MG | Lymphocyte immune globulin | v1, posted December 14, 2022 |
| 1Q22 | $2,355.363 | −$0.171 | 250 MG | Lymphocyte immune globulin | v1, posted June 8, 2022 |
| 4Q21 | $2,355.534 | −$6.737 | 250 MG | Lymphocyte immune globulin | v1, posted June 2, 2022 |
| 3Q21 | $2,362.271 | +$112.427 | 250 MG | Lymphocyte immune globulin | v1, posted June 2, 2022 |
| 2Q21 | $2,249.844 | −$7.801 | 250 MG | Lymphocyte immune globulin | v1, posted March 1, 2022 |
| 1Q21 | $2,257.645 | – | 250 MG | Lymphocyte immune globulin | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.